A meta-analysis of the efficacy of recently introduced diabetes therapies showed the average reduction in HbA1c in response to DPP4 inhibitors, SGLT2 is, and GLP1-RA was 0.53%, 0.79%, and 0.78% respectively. Here, SLC5A2 is linked to diabetes mellitus.